2019 clinical trials in lipid lowering

David I. Feldman, Justin M. Pacor, Roger S. Blumenthal, Khurram Nasir

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Lipid-lowering therapies play a major role in reducing atherosclerotic cardiovascular disease (ASCVD). This article reviews the most recent lipid-lowering therapy trials, many of which provide a unique opportunity to further reduce low-density lipoprotein cholesterol (LDL-C) levels and ASCVD risk on top of statin therapy, and in doing so further decrease the number of future major adverse cardiovascular events. RECENT FINDINGS: Although statin therapy has been the mainstay of treatment for lowering LDL-C levels for many years, many individuals require additional or alternative options for further reducing their risk. Trials on previously studied therapies, such as PCSK9 inhibitors, and new therapies, including inclisiran, bempedoic acid and icosapent ethyl demonstrate significant potential for further lowering of LDL-C levels and risk for events on top of maximally tolerated statin therapy with favourable side effect profiles. SUMMARY: As therapies for ASCVD prevention continue to emerge, clinicians will need to identify the appropriate treatment for individuals based on their estimated risk and risk-enhancing factors. When statin therapy is either not sufficient or patients do not tolerate adequate statin therapy, relying on newer therapies, such as PCSK9-inhibitors, inclisiran, bempedoic acid and icosapent ethyl, will be critical to maximize risk factor profiles to reduce adverse outcomes.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalCurrent opinion in cardiology
Volume35
Issue number4
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of '2019 clinical trials in lipid lowering'. Together they form a unique fingerprint.

  • Cite this